TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T51115	Voltage-gated calcium channel alpha Cav1.2	D01AXB	Duloxetine	Approved	60835	C18H19NOS	297.4	CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32	IC50 = 100000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D01AZG	Risperidone	Approved	5073	C23H27FN4O2	410.5	CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	IC50 = 125000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D05OFX	Lacosamide	Approved	219078	C13H18N2O3	250.29	CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1	IC50 = 50118.72 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D08QMX	Estradiol	Approved	5757	C18H24O2	272.4	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O	IC50 = 50000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D09MWJ	Alfuzosin	Approved	2092	C19H27N5O4	389.4	CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC	IC50 = 199526.23 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0E4DW	Phenytoin	Approved	1775	C15H12N2O2	252.27	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3	IC50 = 125000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0NW3X	Dofetilide	Approved	71329	C19H27N3O5S2	441.6	CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C	IC50 = 158489.32 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0R0FE	Verapamil	Approved	2520	C27H38N2O4	454.6	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	IC50 = 50000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0Z7ZM	Rhucin	Approved	135398744	C22H30N6O4S	474.6	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C	IC50 = 100000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0W8XT	Mibefradil	Phase 1	60663	C29H38FN3O3	495.6	CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F	IC50 = 108000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0YX2B	PMID28460551-Compound-2	Patented	5329102	C22H27FN4O2	398.5	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C	IC50 = 79432.82 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	B0OW6Y	5-[2-[4-[2-[4-(Tetrazol-1-yl)phenyl]acetyl]piperazin-1-yl]ethyl]-3H-2-benzofuran-1-one	Investigative	57331209	C23H24N6O3	432.5	C1CN(CCN1CCC2=CC3=C(C=C2)C(=O)OC3)C(=O)CC4=CC=C(C=C4)N5C=NN=N5	IC50 ~ 100000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	BI4QL7	[2-[(9R)-9-(2-Pyridyl)-6-oxaspiro[4.5]decane-9-yl]ethyl](2-thienylmethyl)amine	Investigative	72712370	C21H28N2OS	356.5	C1CCC2(C1)C[C@](CCO2)(CCNCC3=CC=CS3)C4=CC=CC=N4	IC50 ~ 100000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	BI6KA8	6-[({1-[2-(7-Methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one	Investigative	15982534	C24H28N6O4	464.5	COC1=CC2=C(C=C1)N=CC(=O)N2CCN3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5	IC50 = 92000 nM	Poor binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D06GGT	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)	Investigative	644241	C28H22F3N7O	529.5	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	IC50 = 199526.23 nM	Poor binder